Cryolife Inc (CRY): Ronald D Mccall , director of Cryolife Inc sold 10,000 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $11.56 per share for a total value of $115,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, James Benson (director) sold 5,000 shares at $12.22 per share price.On Apr 19, 2016, C Elkins Ronald (director) sold 1,000 shares at $12.00 per share price.Also, On Mar 4, 2016, James P Mackin (CEO) purchased 10,000 shares at $10.91 per share price.On Mar 1, 2016, David C Gale (VP, Research & Development) sold 150 shares at $9.97 per share price.
Cryolife Inc: On Friday, Jun 3, 2016 heightened volatility was witnessed in Cryolife Inc which led to swings in the share price. The shares opened for trading at $11.67 and hit $11.84 on the upside , eventually ending the session at $11.79, with a gain of 1.20% or 0.14 points. The heightened volatility saw the trading volume jump to 70,073 shares. The 52-week high of the share price is $13 and the company has a market cap of $385 M . The 52-week low of the share price is at $8.94.
Company has been under the radar of several Street Analysts.Cryolife Inc is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 28, 2016.Cryolife Inc is Resumed by Piper Jaffray to Overweight. The Rating was issued on Apr 21, 2016.Cryolife Inc is Initiated by Canaccord Genuity to Buy and the brokerage firm has set the Price Target at $14. The Rating was issued on Apr 13, 2016.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.